This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

American Home Recalling Some Premarin Lots

Another day, another pitfall at American Home (AHP - Get Report).

The Madison, N.J., drugmaker was forced to recall some 50 lots of its top-selling drug Premarin in the last two weeks after the company found some of the pills didn't disolve properly.

Premarin, a widely used hormone replacement therapy for post-menopausal women, is by far American Home's top seller, generating $1.77 billion in 1999 sales. Some 10 million American women currently use Premarin, a cornerstone of American Home's drug division for years. American Home reported 1999 drug sales of $9.5 billion.

American Home said no recalled pills ended up in retail pharmacies or patients, but were recalled from wholesalers this month. The recall was voluntary in consultation with the Food and Drug Administration, it said.

American Home shares were recently trading down $1.56, or 2.4%, at $61.94. Despite the recent setbacks at the drug company, including three failed mergers and a notable product recall, American Home stock has rallied this year, outperforming the drug-stock index and posting a 60%-plus gain.

Booster Shot?

One New York analyst said the recall could give a boost to new competitors in the hormone-replacement therapy market, including Johnson & Johnson's (JNJ) Ortho-Prefest and Pfizer's (PFE) FemHRT.

Growth Spurt
American Home shares outperforming drug index

"The fact that there is some apparent manufacturing or quality control issues does give these guys something of a leg up," said the analyst, who asked to remain anonymous.

That said, the recall isn't likely to seriously hurt prospects for the top-selling hormone replacement therapy. But it marks another embarrassing episode for American Home.

The company has been rocked by ballooning legal costs of another product recall, that of diet drugs Pondimin and Redux in 1997. The drugs were found to cause heart valve problems in some patients, and the company could ultimately end up paying as much as $9 billion in liability and other costs.


Lowell Weiner, an American Home spokesman, said the cost of the recall was "not material." He couldn't immediately say how many pills were involved.

Premarin has been off patent for years, but because the drug is challenging to make, generic competitors haven't had much success in breaking into the market. Premarin, made from the urine of pregnant mares (hence the name Pre-mar-in), has over 100 components. Cenestin, made by Duramed (DRMD), is one competitor, but American Home estimates Cenestin has taken only 1% of the market since approval in 1999.

"Premarin is very difficult to reproduce by any methodology," says American Home COO Robert Essner, speaking at a CIBC World Markets conference this week in New York. "We don't see anyone else coming onto the market anytime soon."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AHP $14.21 0.99%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs